Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

NIH's ClinicalTrials.gov has registered a new bicohort observational study examining real-world utilization and clinical outcomes of a pertuzumab biosimilar in treating breast cancer. The study covers two patient cohorts: neoadjuvant and first-line metastatic disease settings. Researchers will evaluate pathological complete response, disease-free survival, progression-free survival, overall survival, treatment response, and adverse events per CTCAE criteria.

Clinical investigators and healthcare providers conducting breast cancer research should note this study for awareness. Pharmaceutical companies developing or marketing pertuzumab biosimilars may find the real-world effectiveness data relevant to their products. Patients and patient advocacy groups may find this study of interest for understanding current biosimilar research directions.